Symptomatic Non-erosive Gastroesophageal Reflux Disease

DBCOND0148213Gastrointestinal signs and symptoms NEC Gastrointestinal Tract Disorders

Symptomatic Non-erosive Gastroesophageal Reflux Disease is the indication for 2 drugs in DrugBank. It is covered by 2 curated, structured indications.

Also known as: symptomatic non-erosive gastroesphageal reflux disease
Classified under: Gastrointestinal signs and symptoms NEC
Gastrointestinal Tract Disorders
Pharyngeal Diseases
Indicated drugs: Dexlansoprazole
Famotidine

What you can answer from here — as of October 23, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

3Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Symptomatic Non-erosive Gastroesophageal Reflux Disease share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account